Abstract Laron Syndrome (LS)[OMIm# 262500], or primary GH insensitivity, was first
described in 1966 in consanguineous Jewish families from Yemen. LS is characterized by a …

Despite landmark advances in cancer treatments over the last 20 years, cancer remains the
second highest cause of death worldwide, much ascribed to intrinsic and acquired …

Objective Genetically engineered pigs are thought to be an alternative organ source for
patients in end-stage heart failure unable to receive a timely allograft. However, cardiac …

Triple-negative breast cancer (TNBC) is an aggressive breast tumor subtype that currently
lacks targeted treatment options. The role played by the insulin-like growth factor-1 (IGF-1) …

The relationship between growth hormone (GH) excess and cancer is a controversial matter.
Until 2016, most studies in patients with acromegaly found links with colon and thyroid …

The insulin-like growth factor (IGF) system is a dynamic network of proteins, which includes
cognate ligands, membrane receptors, ligand binding proteins and functional downstream …

To date, almost all solid malignancies have implicated insulin-like growth factor (IGF)
signalling as a driver of tumour growth. However, the remarkable level of crosstalk between …

The growth hormone (GH)-insulin-like growth factor-1 (IGF1) signaling pathway emerged in
recent years as a key determinant of aging and longevity. Disruption of this network in …

The growth hormone (GH)–insulin-like growth factor-1 (IGF1) signaling pathway plays a
major role in orchestrating cellular interactions, metabolism, growth and aging. Studies from …

Hepatocellular carcinoma (HCC) is an aggressive neoplasm with poor clinical outcome
because most patients present at an advanced stage, at which point curative surgical …